New coronavirus infection COVID-19: the view of сardiologists (review)
Authors:
Company: 1 Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, 121552, Russian Federation 2 Tver’ «Regional Clinical Hospital», Tver’, Region Tver’, 170036, Russian Federation
For correspondence: Sign in or register.
Type: Editorial article
DOI:
For citation: Golukhova E.Z., Sokolova N.Yu., Bulaeva N.I. New coronavirus infection COVID-19: the view of сardiologists (review). Creative Cardiology. 2020; 14 (1): 5–15 (in Russ.). DOI: 10.24022/1997-3187-2020-14-1-5-15
Received / Accepted: 08.04.2020 / 08.04.2020
Keywords: COVID-19 SARS-CoV-2 cardiovascular disease new coronavirus infection coronavirus
Abstract
In the midst of the global pandemic of the new coronavirus infection COVID-19, development of approaches taking into account the prevailing realities, in the clinical management of special groups of patients comprise a special need. Obviously, that patients with structural heart disease are high risk for adverse outcomes from the coronavirus disease (COVID-19) based on their advanced age and numerous comorbidities. Mortality from COVID-19 in patients aged 70 to 79 years reaches ≥ 8%, aged ≥ 80 years – 14.8%, in the presence of concomitant cardiovascular diseases, regardless of age, up to 10.5%. The main goal in current situation is to ensure timely treatment of cardiac patients, reduce the risk of expose COVID-19, both patients and medical personnel, and optimize the limited resources.References
- Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506. DOI: 10.1016/s0140-6736(20)30183-5
- Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J. Am. Coll. Cardiol. 2020. DOI: 10.1016/j.jacc.2020.03.031
- World Health Organization. WHO DirectorGeneral's opening remarks at the media briefing on COVID-19 – 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-... (accessed March 12, 2020).
- Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu (accessed March 20, 2020).
- Kiselev O.I., Ershov F.I., Malyy V.P., Sologub T.V., Romantsov M.G. (Eds.) Influenza A/H1N1 as a typical emergent infection (virological, clinical and epidemiological features, issues of therapy and prevention): a manual for doctors. St. Petersburg, Kharkiv; Uzhgorod; 2009
- Chuchalin A.G. Influenza: lessons from a pandemic. Pulmonology. Influenza A / H1N1: Lessons from a Pandemic. 2010: 3–8
- Rapezzi C., Ferrari R. The cardiologist at the time of coronavirus: a perfect storm. Eur. Heart J. 2020; 41 (13): 1320–2. DOI: 10.1093/eurheartj/ehaa233
- Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly. 2020; 2 (8): 113–22.
- Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351: 2611–8. DOI: 10.1056/NEJMoa041747
- Davis M.M., Taubert K., Benin A.L., Brown D.W., Mensah G.A., Baddour L.M. et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006; 114: 1549–53. DOI: 10.1161/ CIRCULATIONAHA.106.178242
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–42. DOI: 10.1001/jama.2020.2648
- Su S., Wong G., Shi W. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24: 490–502. DOI: 10.1016/j.tim.2016.03.003
- Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579. DOI: 10.1038/s41586-020-2012-7
- Ching S.F., Hayes L.W., Slakey L.L. Angiotensin-converting enzyme in cultured endothelial cells. Synthesis, degradation and transfer to culture medium. Arteriosclerosis. 1983; 3: 581–8. DOI: 10.1161/01.atv.3.6.581
- Tikhomirova V.E., Kost O.A., Kryukova O.V., Golukhova E.Z., Bulaeva N.I., Zholbaeva A.Z. et al. ACE phenotyping in human heart. PLoS ONE. 2017; 12 (8): e0181976. DOI: 10.1371/journal.pone.0181976
- Turner A.J., Hiscox J.A., Hooper N.M. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol. Sci. 2004; 25: 291–4. DOI: 10.1016/j.tips.2004.04.001
- Zheng Y., Ma Y., Zhang J. et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020. DOI: 10.1038/s41569-020-0360-5
- Kuba K., Imai Y., Rao S., Gao H., Guo F., Guan B. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med. 2005; 11 (8): 875–9. DOI: 10.1038/nm1267. PMID 16007097
- HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists inCOVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statementaddresses-c... (accessed March 19, 2020).
- A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-InternationalSociety-of-Hypertension-on-COVID-19 ( accessed March 20, 2020).
- Statement of the European Society of Hyper-tension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19 https://www.eshonline.org/spotlights/esh-statement-on-covid-19 ( accessed April 8, 2020).
- Statement by the Russian Society of Cardiology on hypertension, ACE inhibitors, angiotensin II receptor blockers and COVID-19. https://covid19cvd-almazovcentre.ru/obzor/tpost/bh6ij4jgkc-ingibitori-apf-blokatori-retseptorovang (accessed March 19, 2020).
- Mourad J.-J., Levy B.I. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat. Rev. Cardiol. 2020. DOI: 10.1038/s41569-020-0368-x
- Frequently asked questions on middle east respiratory syndrome coronavirus (MERS-CoV). 2014. World Health Organization. 9 May 2014. https://www.who.int/csr/disease/coronavirus_infections/faq-09-may-2014/en/ (accessed March 20, 2020).
- Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann. Saudi Med. 2016; 36: 78–80. DOI: 10.5144/0256-4947.2016.78
- Wang D., Hu B., Hu Ch. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–9. DOI: 10.1001/jama.2020.1585
- Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. DOI: DOI: 10.1016/S0140-6736(20)30566-3
- Liu K., Fang Y.Y., Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl.).2020. DOI: DOI: 10.1097/CM9.0000000000000744
- Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020; 8 (4). DOI: 10.1016/S2213-2600(20)30076-X
- Liu Y., Yang Y., Zhang C. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 2020; 63: 364–74. DOI: 10.1007/s11427-020-1643-8
- Wong. C.K., Lam C.W.K., Wu A.K.L., Ip W.K., Lee N.L.S., Chan I.H.S. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004; 136: 95–103. DOI: 10.1111/j.1365-2249.2004.02415.x
- Wood S. COVID-19 and the heart: insights from the front lines. https://www.tctmd.com/news/covid-19-and-heart-insights-front-lines (accessed March 15, 2020).
- Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARSCoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020. DOI: 10.1016/s2213-2600(20)30079-5
- Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis.Herz. 2020. DOI: 10.1007/s00059-020-04909-z
- Zompatori M., Ciccarese F., Fasano L. Overview of current lung imaging in acute respiratory distress syndrome. Eur. Respir. Rev. 2014; 23: 519–30. DOI: 10.1183/09059180.00001314
- Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (4): 844–7. DOI: 10.1111/jth.14768
- Fan B.E., Chong V.C.L., Chan S.S.W. et al. Hematologic parameters in patients with COVID-19 infection. Am. J. Hematol. 2020. DOI: 10.1002/ajh.25774
- Shanghai Clinical Treatment Expert Group for COVID-19. Comprehensive treatment and management of coronavirus disease 2019: expert consensus statement from Shanghai (in Chinese). Chin. J. Infect. 2020; 38.
- Iba T., Levy J.H., Warkentin T.E. et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J. Thromb. Haemost. 2019; 17 (11): 1989–94. DOI: 10.1111/jth.14578
- Iba T., Nisio M.D., Levy J.H., Kitamura N., Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017; 7 (9): e017046. DOI: 10.1136/bmjopen-2017-017046
- Levi M., van der Poll T. Coagulation and sepsis.Thromb. Res. 2017; 149: 38–44. DOI: 10.1016/j.thromres.2016.11.007
- Schmitt F.C.F., Manolov V., Morgenstern J. et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann. Intensive Care. 2019; 9 (1): 19. DOI: 10.1186/s13613-019-0499-6
- Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. JTH. 2020. DOI: 10.1111/jth.14817
- Gupta N., Zhao Y.Y., Evans C.E. The stimulation of thrombosis by hypoxia. Thromb. Res. 2019; 181: 77–83. DOI: 10.1016/j.thromres.2019.07.013
- Luo W., Yu H., Gou J., Li X., Sun Y., Li J., Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19): first case of the whole lung biopsy. Preprints. 2020. DOI: 10.13140/RG.2.2.22934.29762
- Shlyakhto E.V., Konradi A.O. Villeval'de S.V., Zvartau N.E., Yakovlev A.N. et al. Guidelines for the diagnosis and treatment of circulatory system diseases (BSC) in the context of the COVID-19 pandemic (short version). https://scardio.ru/content/Guidelines/COVID-19.pdf. 2020 (accessed March 23, 2020)
- Temporary guidelines of the Ministry of Health of Russia “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, version 4 of 03/27/2020. https://static-3.rosminzdrav.ru/system/attachments/attaches/000/049/877/original/COVID19_recomend_v4... (accessed March 28, 2020)
- Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07/2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000Lbl.pdf (accessed March 22, 2020).
- Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc.,May 2011. https://www.astrazeneca.ca/content/am/azca/downloads/productinformation/brilinta-product%20monograph-en.pdf (accessed March 22, 2020).
- Handbook of COVID-19 prevention and treatment (2020). 16 COVID-19 procedures for hospitals (according to clinical experience from FAHZU). https://www.process.st/covid-19-procedures (accessed March 25, 2020).
- KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert. AbbVie Inc. (per FDA), North Chicago, IL, 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021906s026lbl.pdf (accessed March 22, 2020).
- Page R.L., 2nd, O'Bryant C.L., Cheng D. et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016; 134: e32–69. DOI: 10.1161/cir.0000000000000426
- Tonnesmann E., Kandolf R., Lewalter T. Chloroquine cardiomyopathy – a review of the lite-rature. Immunopharmacol. Immunotoxicol. 2013; 35: 434–42. DOI: 10.3109/08923973.2013.780078
- Wu Q. Zhou L., Sun X. et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci. Rep. 2017; 7 (1): 9110. DOI: 10.1038/s41598-017-09536-z
- Welt F.G.P., Shah P.B., Aronow H.D., Bortnick A.E., Henry T.D. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC's interventional council and SCAI. J. Am. Coll. Cardiol. 2020. DOI: 10.1016/ j.jacc.2020.03.021